SCHEMBL30794826

SCHEMBL30794826

CCN(CC)c1nc2ccccc2c(=O)n1NC(=O)Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
HTT P42858 5/20 0.61
LMNA P02545 3/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
NPSR1 Q6W5P4 1/20 0.56
RXFP1 Q9HBX9 1/20 0.55
RAB9A P51151 3/20 0.53
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
EGFR P00533 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
GALR3 O60755 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
USP2 O75604 1/20 0.47
TP53 P04637 1/20 0.47
ALOX15 P16050 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2751773 1.00 ALDH1A1 (0.61) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2750992 0.92 ALDH1A1 (0.66) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL30794703 0.91 ALDH1A1 (0.54) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2751212 0.91 ALDH1A1 (0.54) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2749142 0.90 ALDH1A1 (0.57) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL30796026 0.90 ALDH1A1 (0.57) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2751205 0.89 ALDH1A1 (0.50) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL30796035 0.89 ALDH1A1 (0.50) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL30794301 0.84 ALDH1A1 (0.49) ALDH1A1HTTLMNAMEN1KMT2A
SCHEMBL2750321 0.84 ALDH1A1 (0.49) ALDH1A1HTTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed